HIV/AIDS Vaccines: 2018
Human immunodeficiency virus (HIV) has infected 76 million people and killed an estimated 35 million. During its 40‐year history, remarkable progress has been made on antiretroviral drugs. Progress toward a vaccine has also been made, although this has yet to deliver a licensed product. In 2007, I w...
Gespeichert in:
Veröffentlicht in: | Clinical pharmacology and therapeutics 2018-12, Vol.104 (6), p.1062-1073 |
---|---|
1. Verfasser: | |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Human immunodeficiency virus (HIV) has infected 76 million people and killed an estimated 35 million. During its 40‐year history, remarkable progress has been made on antiretroviral drugs. Progress toward a vaccine has also been made, although this has yet to deliver a licensed product. In 2007, I wrote a review, HIV AIDS Vaccines: 2007. This review, HIV AIDS Vaccines: 2018, focuses on the progress in the past 11 years. I begin with key challenges for the development of an AIDS vaccine and the lessons learned from the six completed efficacy trials, only one of which has met with some success. |
---|---|
ISSN: | 0009-9236 1532-6535 |
DOI: | 10.1002/cpt.1208 |